Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01068873 · ClinicalTrials.gov registry record · Phase 4
Kaletra and Maraviroc in Antiretroviral Therapy (ART)-Naive Patients (KALMAR Study)
A Phase 4 study, sponsored by Temple University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 1
- Enrollment target
NCT01068873: Clinical Trial Phase 4 study, sponsored by Temple University.
NCT01068873 is a Phase 4 study that was terminated before completion, run by Temple University. The registered enrollment target is 1 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01068873, a Phase 4 study, was terminated before completion, sponsored by Temple University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 1 participants
- Enrollment target
Study Summary
The primary objective of this pilot study is to assess the efficacy of lopinavir/ritonavir (Kaletra, a protease inhibitor, PI) when used in combination with maraviroc (Selzentry, an HIV entry inhibitor) for the treatment of antiretroviral naïve HIV infected patients. Twenty patients will be enrolled and studied for 48 weeks.
Interventions
- DRUG lopinavir/ritonavir plus maraviroc
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2010-04 |
| Est. Completion | 2010-12 |
| Phase | Phase 4 |
Why NCT01068873 stopped before completion
NCT01068873 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 1 intervention - of which lopinavir/ritonavir plus maraviroc is the first listed.
NCT01068873 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01068873 about?
NCT01068873 is a clinical study titled "Kaletra and Maraviroc in Antiretroviral Therapy (ART)-Naive Patients (KALMAR Study)". The primary objective of this pilot study is to assess the efficacy of lopinavir/ritonavir (Kaletra, a protease inhibitor, PI) when used in combination with maraviroc (Selzentry, an HIV entry inhibitor) for the treatment of antiretroviral naïve HIV infected patients. Twenty patients will be enrolled...
What is the current status of trial NCT01068873?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 1 participants. The study started on 2010-04. Estimated completion is 2010-12.
What interventions are being tested in trial NCT01068873?
The interventions under investigation include: lopinavir/ritonavir plus maraviroc (DRUG).
Who is sponsoring clinical trial NCT01068873?
This trial is sponsored by Temple University, which has 163 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01068873's enrollment target sits among peer trials
1 2000th of 2000 the lowest of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia